PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19+
SponsorKarolinska University Hospital

About this trial

Cancers of the pancreas, bile ducts, stomach and ovaries are dismal diseases with most patients being diagnosed in advanced stages leading to a bad prognosis. These cancers can be difficult to diagnose and sometimes impossible to differentiate from underlying benign conditions. Establishing the correct diagnosis of primary cancer lesions and possible spread to other organs in time is pivotal for choosing the right therapy. Routinely applied staging procedures are however not always reliable. The main aim in this study is to evaluate the diagnostic accuracy of PET/CT with a novel radiotracer, FAPI, in the primary diagnosis of cancers in the pancreas, stomach and bile ducts as well as in patients with primary and recurrent epithelial ovarian cancer (EOC).

Eligibility criteria

Qualifiers

Consecutive patients scheduled for surgical removal of either a pancreatic, biliary or gastric lesion.

Signed informed consent.

Disqualifiers

Age ≤18 year

Pregnancy and lactation

Significantly reduced renal function

Allergy to iodinated contrast media

Trial design

Treatments tested in this trial

  • 68Ga-FAPI-46
  • PET/CT

Treatment groups

410 Participants
are divided into 2 treatment groups

Sponsors and collaborators